Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption.
about
The endothelin axis: emerging role in cancerProbing the invasiveness of prostate cancer cells in a 3D microfabricated landscapeCharacterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.Prostate cancer and bone: the elective affinities.Mechanism of cancer pain.Novel therapies for metastatic castrate-resistant prostate cancer.A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancerThe host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Endothelin-1: a multifunctional molecule in cancer.Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.The PCa Tumor Microenvironment.Cancer-targeted therapies and radiopharmaceuticalsPhysiopathology of spine metastasis.Atrasentan: targeting the endothelin axis in prostate cancer.A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.Mechanisms of cancer metastasis to the bone.Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications.Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases.Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.Endothelin receptor antagonists in cancer therapy.Molecular mechanisms of metastasis in prostate cancer.Docetaxel-based combination therapy for castration-resistant prostate cancer.Zibotentan for the treatment of castrate-resistant prostate cancer.Bone metastases: molecular mechanisms and novel therapeutic interventions.Novel targeted agents on the horizon for castration-resistant prostate cancer.Steps in prostate cancer progression that lead to bone metastasisNew therapeutic targets for cancer bone metastasisTransforming growth factor-β signaling induced during prostate cancer cell death and neuroendocrine differentiation is mediated by bone marrow stromal cells.Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens.Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization.In vitro design of mesenchymal to epithelial transition of prostate cancer metastasis using 3D nanoclay bone-mimetic scaffolds.Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis.
P2860
Q28206793-A2A6DBB1-A38D-42FF-B9F1-41D5C981D805Q30499933-187B5976-415B-4558-B2BB-2C6F32BA70CBQ30596578-E47D6ED2-D142-4717-82E5-CCB144CE4793Q33757791-DA0BDD71-AB46-4B1D-849F-FAC8332B2415Q33953901-8ECED15B-6861-4A40-8BE4-50E4E2429F0DQ34249263-FE2AB285-79C2-41A1-BA22-C8F424DE64E1Q34433349-BBBCFFD0-7CA5-4B11-9389-843EA7FC0032Q34699785-A65C94A1-9EEB-4517-A9F2-579803D4C29DQ35074833-8C6F9EF9-0A11-4778-AEB6-6A9FC959D267Q35149069-ED7CA9C8-BB53-4022-9F1E-1696744C6336Q35550375-450089AD-8333-45B7-94F4-AE902DB63AF5Q35603143-9E3064AD-6A82-491F-98F8-903DA7E1057CQ35683440-C9622321-A458-48AC-AEC5-C5136F6CBE81Q35692236-08301B93-6F7E-40EB-B31E-8AF7DE399092Q35964727-DB68C0FF-3EEA-418A-B209-EEED4856C88AQ35978728-6E76663A-3977-4303-89B9-A422A987F653Q36027386-3668B7E0-A840-46A2-8975-21F41B607757Q36185608-7C604622-C2A1-4F63-A4D4-0529D57A95F5Q36352082-85F818C1-CAE8-4E04-B51B-29F0286A36EBQ36707418-A51100D7-5C33-41B5-AE00-AC8DA43E57EAQ36848283-194916AC-0679-4788-9B60-19C0C01B325BQ37024077-75DD4F1C-0A20-438F-93AF-E993EACCC810Q37339692-5FD0B1E5-8A6F-4DEF-BD7D-5458DE38436CQ37721016-DF734DA8-217D-4939-9674-2BF829752DE9Q37760222-596EAD0C-1219-4BD6-BF1A-4E736E727A7BQ37785505-1ECB91DA-4285-49EB-94EB-EB0AFF3C98EFQ37818294-F7BE9466-82BB-4D88-9A18-C38DC3878CECQ37848782-AF5EED51-418A-4123-863A-30C4E1F85B3EQ38473066-1CBAA976-EC88-49E9-B9AB-0945E99ACDBAQ38833670-EA9782B1-1752-446D-B12D-28F1CE406A57Q40741627-D9A992AB-BB16-44FA-93EC-9B4D04EBEF31Q40762950-DBDE6704-998D-449D-9DBE-0C01780795A4Q41877818-14680627-FAB5-414B-AB3D-95235560E44EQ48028249-36AA3A18-2581-4CC4-A372-753CE80B4727Q55235695-9A9CB50A-08BE-4685-9C9A-A7CD01F86E28
P2860
Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Endothelin-1 from prostate can ...... osteoclastic bone resorption.
@en
type
label
Endothelin-1 from prostate can ...... osteoclastic bone resorption.
@en
prefLabel
Endothelin-1 from prostate can ...... osteoclastic bone resorption.
@en
P2093
P2860
P356
P1476
Endothelin-1 from prostate can ...... osteoclastic bone resorption.
@en
P2093
Kancherla R
Mittelman A
Wu-Wong JR
P2860
P2888
P304
P356
10.1054/BJOC.2000.1261
P407
P577
2000-08-01T00:00:00Z
P5875
P6179
1005797253